Murielle Roussel - Concepedia

Author

Murielle Roussel

Also Known As

M Roussel, M. Roussel, Muriel Roussel, Murielle ROUSSEL, Murielle Roussel, ROUSSEL, Mikaël, Roussel, Mikael, Roussel, Murielle, murielle Roussel

269

Publications

10.1K

Citations

H-Index

Concepts

All Affiliations

Sorbonne Université Hôpital Saint-Antoine Institut universitaire du cancer de Toulouse Oncopole Hôpital Claude Huriez Institut Paoli-Calmettes

About

Murielle Roussel is an author at Sorbonne Université specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	21	2K
2	Health Sciences	11	12	1.4K
3	Public Health	1	1	85
4	Cell Biology	1	1	100
5	Cellular Therapies	1	1	19

Murielle Roussel

Publications

8.7K

Citations

H-Index

Page 1

	Year	Citations
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma Michel Attal, Valérie Lauwers‐Cancès, Cyrille Hulin, New England Journal of Medicine	2017	1.2K
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma Michel Attal, Valérie Lauwers‐Cancès, Gérald Marit, New England Journal of Medicine	2012	1.1K
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study Philippe Moreau, Michel Attal, Cyrille Hulin, The Lancet Hematological MalignancyRadiation OncologyMedicineImmunologyHematology	2019	922
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera Jean‐Jacques Kiladjian, Bruno Cassinat, Sylvie Chevret, Blood	2008	567
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p) Hervé Avet‐Loiseau, Xavier Leleu, Murielle Roussel, Journal of Clinical Oncology	2010	419
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial Philippe Moreau, Cyrille Hulin, Margaret Macro, Blood	2016	273
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma Thierry Façon, Meletios Α. Dimopoulos, Angela Dispenzieri, Blood	2017	267
Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome Murielle Roussel, Valérie Lauwers‐Cancès, Nelly Robillard, Journal of Clinical Oncology	2014	263
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02 Xavier Leleu, Michel Attal, Bertrand Arnulf, Blood	2013	208
Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myélome (IFM) Murielle Roussel, Philippe Moreau, Anne Huynh, Blood	2009	171

Page 1